Author details

Full Name

Colm Morrissey

Affiliation

ORCID

Career Start Year

1998

Papers

153

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
36993422	GD2 and its biosynthetic enzyme GD3 synthase promote tumorigenesis in prostate cancer by regulating cancer stem cell behavior.	bioRxiv	2024
37850574	Characterization of HOXB13 expression patterns in localized and metastatic castration-resistant prostate cancer.	J Pathol	2024
37796107	Targeting the fibroblast growth factor pathway in molecular subtypes of castration-resistant prostate cancer.	Prostate	2024
37531417	Exportin 1 inhibition prevents neuroendocrine transformation through SOX2 down-regulation in lung and prostate cancers.	Sci Transl Med	2023
36399432	Nucleosome Patterns in Circulating Tumor DNA Reveal Transcriptional Regulation of Advanced Prostate Cancer Phenotypes.	Cancer Discov	2023
37940068	Androgen receptor inhibition suppresses anti-tumor neutrophil response against bone metastatic prostate cancer via regulation of TÎ²RI expression.	Cancer Lett	2023
37823778	Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers.	Cancer Res Commun	2023
37995683	Temporal evolution reveals bifurcated lineages in aggressive neuroendocrine small cell prostate cancer trans-differentiation.	Cancer Cell	2023
37905039	ONECUT2 Activates Diverse Resistance Drivers of Androgen Receptor-Independent Heterogeneity in Prostate Cancer.	bioRxiv	2023
37636316	Co-evolution of <i>AR</i> gene copy number and structural complexity in endocrine therapy resistant prostate cancer.	NAR Cancer	2023
37347559	Chemokine receptor CXCR7 activates Aurora Kinase A and promotes neuroendocrine prostate cancer growth.	J Clin Invest	2023
37400528	Androgen-regulated stromal complement component 7 (C7) suppresses prostate cancer growth.	Oncogene	2023
36821396	Reversible epigenetic alterations mediate PSMA expression heterogeneity in advanced metastatic prostate cancer.	JCI Insight	2023
37440313	LSD1 promotes prostate cancer reprogramming by repressing TP53 signaling independently of its demethylase function.	JCI Insight	2023
37041154	Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy.	Nat Commun	2023
35131885	The Movember Global Action Plan 1 (GAP1): Unique Prostate Cancer Tissue Microarray Resource.	Cancer Epidemiol Biomarkers Prev	2022
36109521	Transcriptional profiling of matched patient biopsies clarifies molecular determinants of enzalutamide-induced lineage plasticity.	Nat Commun	2022
35909568	The Role of Epigenetic Change in Therapy-Induced Neuroendocrine Prostate Cancer Lineage Plasticity.	Front Endocrinol (Lausanne)	2022
36369237	Stromal FOXF2 suppresses prostate cancer progression and metastasis by enhancing antitumor immunity.	Nat Commun	2022
35562350	MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets.	Nat Commun	2022
36337169	Comprehensive assessment of anaplastic lymphoma kinase in localized and metastatic prostate cancer reveals targetable alterations.	Cancer Res Commun	2022
35552660	Therapeutic Implications for Intrinsic Phenotype Classification of Metastatic Castration-Resistant Prostate Cancer.	Clin Cancer Res	2022
35468964	HOXB13 suppresses de novo lipogenesis through HDAC3-mediated epigenetic reprogramming in prostate cancer.	Nat Genet	2022
35014711	Paracrine Wnt signaling is necessary for prostate epithelial proliferation.	Prostate	2022
34877933	Genomic attributes of homology-directed DNA repair deficiency in metastatic prostate cancer.	JCI Insight	2021
33792558	The heterogeneity of prostate cancers lacking AR activity will require diverse treatment approaches.	Endocr Relat Cancer	2021
33471819	Cabozantinib can block growth of neuroendocrine prostate cancer patient-derived xenografts by disrupting tumor vasculature.	PLoS One	2021
33785741	Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer.	Nat Commun	2021
34145028	BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program.	Clin Cancer Res	2021
33658518	Inter- and intra-tumor heterogeneity of metastatic prostate cancer determined by digital spatial gene expression profiling.	Nat Commun	2021
34312180	RNA Splicing Factors SRRM3 and SRRM4 Distinguish Molecular Phenotypes of Castration-Resistant Neuroendocrine Prostate Cancer.	Cancer Res	2021
33199493	Regulation of CEACAM5 and Therapeutic Efficacy of an Anti-CEACAM5-SN38 Antibody-drug Conjugate in Neuroendocrine Prostate Cancer.	Clin Cancer Res	2021
34493733	Transcriptional network involving ERG and AR orchestrates Distal-lessÂ homeobox-1 mediated prostate cancer progression.	Nat Commun	2021
33009488	De novo induction of lineage plasticity from human prostate luminal epithelial cells by activated AKT1 and c-Myc.	Oncogene	2020
32414837	Correction: Activation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate Cancer.	Cancer Res	2020
31894239	Inhibitory Interplay of SULT2B1b Sulfotransferase with AKR1C3 Aldo-keto Reductase in Prostate Cancer.	Endocrinology	2020
32114681	Neutrophils are mediators of metastatic prostate cancer progression in bone.	Cancer Immunology, Immunotherapy	2020
32403054	Alternative splicing of LSD1+8a in neuroendocrine prostate cancer is mediated by SRRM4.	Neoplasia	2020
31932493	Diverse <i>AR</i> Gene Rearrangements Mediate Resistance to Androgen Receptor Inhibitors in Metastatic Prostate Cancer.	Clin Cancer Res	2020
32461304	Targeting RET Kinase in Neuroendocrine Prostate Cancer.	Mol Cancer Res	2020
32460015	Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication Stress.	Cell Rep	2020
31806771	Differential Expression of Glucose Transporters and Hexokinases in Prostate Cancer with a Neuroendocrine Gene Signature: A Mechanistic Perspective for <sup>18</sup>F-FDG Imaging of PSMA-Suppressed Tumors.	J Nucl Med	2020
31806643	Identification of Therapeutic Vulnerabilities in Small-cell Neuroendocrine Prostate Cancer.	Clin Cancer Res	2020
33260953	Inhibition of Serum Response Factor Improves Response to Enzalutamide in Prostate Cancer.	Cancers (Basel)	2020
33042443	FOXA2 promotes prostate cancer growth in the bone.	Am J Transl Res	2020
32901137	EGFR as a stable marker of prostate cancer dissemination to bones.	Br J Cancer	2020
31376206	Testosterone accumulation in prostate cancer cells is enhanced by facilitated diffusion.	Prostate	2019
30511964	Targeting FOXA1-mediated repression of TGF-Î² signaling suppresses castration-resistant prostate cancer progression.	J Clin Invest	2019
30578319	Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer.	Proc Natl Acad Sci U S A	2019
30334814	Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer.	J Clin Invest	2019